Spoken Alpha
Centessa Pharmaceuticals plc
Centessa Pharmaceuticals develops small-molecule orexin receptor 2 agonists to treat sleep-wake and neuropsychiatric disorders. Its lead candidate, cleminorexton, is in late-stage clinical trials for narcolepsy and idiopathic hypersomnia, with follow-up candidates ORX142 and ORX489 in earlier development.
Centessa Pharmaceuticals plc is a Healthcare company operating in Biotechnology with a $6.27B market cap.
CNTA missed consensus EPS by 0.4% in Q1 FY2026, reported May 17, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add CNTA, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CNTA.
$ curl https://api.spokenalpha.com/v1/companies/CNTAFAQ
Spoken Alpha indexes CNTA's earnings call transcripts at https://spokenalpha.com/companies/CNTA. Each call links to attributed speakers and parsed analyst Q&A. Centessa Pharmaceuticals plc's own investor relations page is at https://investors.centessa.com/.
Centessa Pharmaceuticals plc (CNTA) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-17 | $-0.52 | $-0.38 | -35.5% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-25 | $-0.48 | $-0.38 | -24.9% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-0.41 | $-0.39 | -5.1% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.38 | $-0.33 | -15.3% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-13 | $-0.20 | $-0.36 | +44.4% | $15.0M | — | — | EODHD |
| Q4 FY2024 | 2025-03-23 | $-0.84 | $-0.42 | -100.0% | $952.3K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.37 | $-0.40 | +6.6% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.40 | $-0.39 | -2.6% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-0.38 | $-0.42 | +9.5% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-27 | $-0.38 | $-0.48 | +20.8% | $6.9M | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.40 | $-0.52 | +23.1% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.26 | $-0.49 | +46.9% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-11 | $-0.53 | $-0.41 | -29.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $-0.45 | $-0.48 | +6.3% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.57 | $-0.56 | -1.8% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $-0.69 | $-0.57 | -21.1% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.60 | $-0.70 | +14.3% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-29 | $-0.68 | $-0.60 | -13.3% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-0.45 | $-0.55 | +18.2% | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-0.65 | $-0.66 | +1.5% | $0 | — | — | EODHD |
Source: EODHD. CNTA reported actuals as published; sparse fields render as —.